RecruitingNot ApplicableNCT06791226
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/ CT in Patients With Orbital Neoplasms and Compared With 18F-FDG PET/ CT
Sponsor
Peking University Third Hospital
Enrollment
50 participants
Start Date
Jul 16, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in orbital neoplasms, and compared with 18F-FDG PET/CT.
Eligibility
Min Age: 3 YearsMax Age: 80 Years
Inclusion Criteria3
- patients with suspected or newly diagnosed orbital neoplasms (supporting evidence may include MRI, CT and pathology report);
- patients who had scheduled both 18F-FDG and 18F-AlF-FAPI PET/CT scans;
- patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria3
- patients with pregnancy;
- breastfeeding;
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TEST18F-AlF-FAPI PET/CT, 18F-FDG PET/CT
Subjects with orbital neoplasms underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT for diagnosis and staging.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06791226